Clinical Trial: Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.

U.S., Dec. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07266480) titled 'Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.' on Aug. 18.

Brief Summary: Evaluating the efficacy and safety of adebrelizumab for the adjuvant treatment of esophageal squamous cell cancer.

Study Start Date: Sept. 01

Study Type: INTERVENTIONAL

Condition: Squamous Oesophageal Cancer

Intervention: DRUG: Adebrelizumab

Patients undergoing radical surgery to achieve R0 resection were randomised in a 1:1 ratio at 4-16 weeks postoperatively, with patients in the trial group receiving adjuvant treatment with adebrelizumab (up to 17 cycles)

Recruitment Status: RECRUITING

Sponsor: Hebei ...